0
0
The aim of the randomized trial is to evaluate potentially efficacious candidate vaccines, and to possibly contribute to ending the ongoing outbreak and protect populations at risk in the future
BRAZZAVILLE, Congo (Republic of the), November 17, 2022/APO Group/ –As the first doses of candidate vaccines against the Sudan ebolavirus are expected to arrive in Uganda in the coming days, World Health Organization (WHO) is boosting efforts to support the government-led response against the outbreak which has now affected nine districts, including three complex urban environments.
A WHO committee of external experts has evaluated three candidate vaccines and agreed that they all be deployed to Uganda for a clinical trial against the Sudan ebolavirus—one of the six species of the Ebolavirus genus. Unlike the Zaire ebolavirus which has sparked most of the recent outbreaks, there are no approved vaccines or therapeutics for the Sudan ebolavirus.
The aim of the randomized trial is to evaluate potentially efficacious candidate vaccines, and to possibly contribute to ending the ongoing outbreak and protect populations at risk in the future. The trial is the result of a collaborative effort, coordinated by WHO with developers, academic institutions, countries’ sponsoring the production of the vaccine doses, regulatory authorities, other experts and the government of Uganda.
Supplies of one of the three candidate vaccines are expected to arrive in Uganda next week and the other two soon after. The trial protocol has been conditionally approved by WHO and Uganda and the final approvals are expected soon. Import permits for the vaccines is expected to be issued by the National Regulatory Authority soon. While the trial start date is not certain yet, WHO is working with the Ministry of Health and Makerere University, which is leading the trial to make sure everything is ready and the trial can begin once one vaccine has arrived and all the trial preparations are in place.. The two other candidates will be added, as they become available.
“The start of vaccine trials will mark a pivotal moment towards the development of an effective tool against the virus behind the current Ebola outbreak in Uganda,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “In previous outbreaks, we have seen how effective vaccines have averted the further spread of the virus, helping to quickly contain the epidemic. But it will take time to get trial results and for now the outbreak can be controlled without vaccines as we can see already with the slowing down of transmission in many of the affected districts.
Uganda declared an outbreak of Sudan ebolavirus on 20 September. As of 14 November 2022, there have been 141 confirmed and 22 probable cases (total of 163 cases) and 55 confirmed and 22 probable deaths (77 total deaths) reported. Nineteen health workers have been infected with the virus and seven have died.
On 11 November, the eastern Jinja district, which hosts Jinja city, became the third urban area—after the capital of Kampala and Masaka city—to detect the virus. Jinja, located on the shores of Lake Victoria, is home to some 300 000 people. While Jinja is now impacted by Ebola, the outbreak is slowing down in six districts, with two dropping from the follow-up list as they have reported no cases in over 42 days.
The start of vaccine trials will mark a pivotal moment towards the development of an effective tool against the virus behind the current Ebola outbreak in Uganda
“The confirmation of Ebola cases in a new district is a concern and places a further strain on the control efforts. With their highly mobile residents and often crowded environments, cities favour the spread of the virus, but Uganda has progressively ramped up the response, keeping pace with the evolving situation. WHO and partners are helping to trace, find, test, care for people with the virus and work with communities,” Dr Moeti said. “But with the virus constantly on the move, we must press even harder to stay ahead.”
Dr Moeti is wrapping up a three-day mission to Uganda, where she met with health authorities, key partners and visited Kassanda and Mubende districts the initial epicentre of the outbreak.
In support of the outbreak response WHO has deployed 80 experts and supported health authorities with the deployment of additional 150 experts, including over 60 epidemiologists. Due to the infectious nature of the Sudan ebolavirus Personal Protective Equipment (PPE) which include gowns, gloves, eye protection and medical masks are critical for provision of safe care to patients. WHO recently delivered 15 000 PPE to Uganda, which are enough to protect health workers caring for patients admitted in the current Ebola treatment units for 30 days. The Organization has helped train nearly 1000 health workers and village health team members in contact tracing, and another 1155 health workers in infection prevention and control in health facilities.
WHO has also launched a US$ 88.2 million appeal to fight the outbreak and support Ebola readiness in neighbouring countries. So far, only 20% of the funds has been received.
“Dedicated response teams are putting incredible efforts on the frontlines to safeguard communities and require robust support to effectively deliver on this crucial task. We must not fail them,” said Dr Moeti. “Ebola’s disruptive force is most stark among communities whose lives have been upended and among families who have lost loved ones.”
The ongoing Sudan ebolavirus outbreak is Uganda’s fifth of its kind. Seven cases and four deaths were recorded in the country’s previous Sudan ebolavirus outbreak in 2012.
Dr Moeti spoke today during a press conference. She was joined by Lt. Col Dr Henry Kyobe Bossa, Incident Commander, Ebola outbreak, Ministry of Health, Uganda.
Also on hand from WHO to answer questions were Dr Yonas Tegegn, WHO Representative in Uganda, Dr Patrick Otim, Incident Manager for the Uganda Ebola outbreak; Dr Ana Maria Henao-Restrepo, Co-Lead Research and Development Blueprint for epidemics, Health Emergencies Programme; Dr Walter Fuller, Technical Officer, Antimicrobial Resistance Programme; and Dr Cheick Diallo, Technical Officer, Strategic Information.
About Author
OTHER ARTICLES
Zambia : The vital role of community health assistants in public health surveillance
Lusaka — African health ministers and partners are calling for increased investment in integrated health services to address the growing burden of severe noncommunicable diseases (NCDs), particularly those affecting women and underserved populations across the region. At a high-level side event during the Seventy-fifth session of the WHO Regional Committee for Africa, delegates emphasized the urgent need for equitable access to prevention, screening, treatment, and rehabilitation across the continuum of care for NCDs. Disparities are especially pronounced in rural areas, where health infrastructure and services remain inadequate. Breast and cervical cancers are among the leading causes of cancer-related deaths among women in sub-Saharan Africa—particularly cervical cancer, which is both preventable and treatable. It remains the most common cause of cancer death for women in the region. In 2022, Africa accounted for nearly a quarter (23%) of the 76 000 global cervical cancer deaths. Meanwhile, severe NCDs such as Type 1 diabetes, sickle cell disease, and heart conditions claim more than half a million lives annually, including among children, adolescents, and young adults in some of the continent’s poorest communities. Inequitable access to health services continues to hinder efforts to reduce this burden. To improve cervical and breast cancer care in the region, urgent investment is needed in leadership, governance, and financing. Strengthening these foundations is critical in the current funding landscape. Advancements in strategic planning, healthcare infrastructure, workforce training, and—most importantly—equitable access to screening, diagnostic, and treatment services are essential. To address these challenges, WHO and its partners showcased successful integrated models such as the Women’s Integrated Care for Cancer Services (WICS), the BEAT Breast Cancer Project, and the PEN-Plus Strategy. WICS strengthens early detection, treatment, and integration of women’s cancer services into primary health care systems in Côte d’Ivoire, Kenya, and Zimbabwe. The BEAT Breast Cancer Project is a transformative multi-year initiative aimed at reducing breast cancer mortality among women in Tanzania and Ghana through early detection, timely diagnosis, and comprehensive treatment access. “PEN-Plus, WICS and the BEAT Breast Cancer Initiative are models for a new standard of care, rooted in equity, access and health justice. I urge countries to prioritize policies that embed these models into broader health system strengthening, said Dr Mohamed Janabi, WHO Regional Director for Africa”. Côte d’Ivoire offers a compelling example of progress, combining high HPV vaccination coverage—reaching over three million girls (91.4%)—with WICS-supported community-based screening campaigns to strengthen cervical cancer prevention. In Kenya, cervical cancer screening has been successfully integrated into national health services. “This gathering marks a pivotal moment to accelerate action for breast cancer prevention in Africa. We deeply value the leadership of the Ministries of Health of Ghana and Tanzania, and the steadfast support of the Pfizer Foundation in helping us achieve this milestone. The side event builds momentum for the policy prioritization of women’s cancers, partnerships to strengthen the broader women’s cancer ecosystem, and advance a health-systems approach to breast cancer prevention and management”, said Dr Somesh Kumar, Senior Director, Jhpiego. PEN-Plus expands access to care for severe NCDs at the district hospital level. Since its implementation, 20 countries in Africa have increased access to services for severe NCDs. Over 15 000 people are currently receiving treatment for chronic conditions such as sickle cell disease and Type 1 diabetes through PEN-Plus clinics.
Confirmed Case of Mpox in Senegal: Situation Update (as of August 27, 2025)